PMID- 31909368
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 2508-7576 (Electronic)
IS  - 2508-6235 (Print)
IS  - 2508-6235 (Linking)
VI  - 28
IP  - 4
DP  - 2019 Dec
TI  - Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 
      Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus 
      and Coronary Artery Disease.
PG  - 254-261
LID - 10.7570/jomes.2019.28.4.254 [doi]
AB  - BACKGROUND: Randomized controlled trials demonstrated lowering risks of 
      cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in 
      patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We 
      analyzed the effects of cardiovascular function on SGLT2 inhibitors compared with 
      dipeptidyl peptidase-4 (DPP4) inhibitors in T2DM with atherosclerotic 
      cardiovascular disease (ASCVD) or heart failure (HF). METHODS: This is a 
      retrospective, observational, single center study. Data from 89 patients with 
      ASCVD or HF from January 2015 to February 2018 were analyzed regarding the effect 
      of SGLT2 inhibitors and DPP4 inhibitors. Cardiovascular function was assessed by 
      2-D echocardiography and N-terminal prohormone of brain natriuretic peptide 
      (NT-pro BNP). RESULTS: A total of 89 patients with T2DM were considered in two 
      groups of SGLT2 inhibitors (n=41) and DPP4 inhibitors (n=48). The mean follow-up 
      period was 2 years, with a total of 89 patient-years. Despite no significant 
      change in systolic function, SGLT2 inhibitors improved cardiovascular function, 
      as demonstrated by a reduced left ventricular ejection fraction less than 40%, 
      ratio of mitral peak velocity of early filling velocity to early diastolic mitral 
      annular velocity, ratio of early to late ventricular filling velocities, and 
      NT-pro BNP compared with the DPP4 inhibitor group. CONCLUSION: SGLT2 inhibitors 
      improve cardiovascular function in T2DM with coronary artery disease compared to 
      DPP4 inhibitors.
CI  - Copyright (c) 2019 Korean Society for the Study of Obesity.
FAU - Lee, Sook Jung
AU  - Lee SJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
FAU - Lee, Kook Hyung
AU  - Lee KH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
FAU - Oh, Hyun Geong
AU  - Oh HG
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
FAU - Seo, Hye Ji
AU  - Seo HJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
FAU - Jeong, Soo Jin
AU  - Jeong SJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
FAU - Kim, Chong Hwa
AU  - Kim CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong 
      General Hospital, Bucheon, Korea.
LA  - eng
PT  - Journal Article
DEP - 20191230
PL  - Korea (South)
TA  - J Obes Metab Syndr
JT  - Journal of obesity & metabolic syndrome
JID - 101704724
PMC - PMC6939702
OTO - NOTNLM
OT  - Coronary artery disease
OT  - Diabetes Mellitus
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Sodium-glucose cotransporter-2
COIS- CONFLICTS OF INTEREST The authors declare no conflict of interest.
EDAT- 2020/01/08 06:00
MHDA- 2020/01/08 06:01
PMCR- 2019/12/01
CRDT- 2020/01/08 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2019/10/31 00:00 [revised]
PHST- 2019/11/28 00:00 [accepted]
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/01/08 06:01 [medline]
PHST- 2019/12/01 00:00 [pmc-release]
AID - jomes-28-4-254 [pii]
AID - 10.7570/jomes.2019.28.4.254 [doi]
PST - ppublish
SO  - J Obes Metab Syndr. 2019 Dec;28(4):254-261. doi: 10.7570/jomes.2019.28.4.254. 
      Epub 2019 Dec 30.